PE20221173A1 - Anticuerpo multiespecifico con especificidad de union para il-13 e il-17 humanas - Google Patents

Anticuerpo multiespecifico con especificidad de union para il-13 e il-17 humanas

Info

Publication number
PE20221173A1
PE20221173A1 PE2022001104A PE2022001104A PE20221173A1 PE 20221173 A1 PE20221173 A1 PE 20221173A1 PE 2022001104 A PE2022001104 A PE 2022001104A PE 2022001104 A PE2022001104 A PE 2022001104A PE 20221173 A1 PE20221173 A1 PE 20221173A1
Authority
PE
Peru
Prior art keywords
human
cdr
seq
sequence provided
multispecific antibody
Prior art date
Application number
PE2022001104A
Other languages
English (en)
Spanish (es)
Inventor
Adnan Rahman Khan
Sam Philip Heywood
David Paul Humphreys
Daniel John Lightwood
Emma Dave
Emily Mary Cairistine Barry
Sarah Jayne Stanyon
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of PE20221173A1 publication Critical patent/PE20221173A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2022001104A 2019-12-20 2020-12-18 Anticuerpo multiespecifico con especificidad de union para il-13 e il-17 humanas PE20221173A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1919061.0A GB201919061D0 (en) 2019-12-20 2019-12-20 Multi-specific antibody
PCT/EP2020/087046 WO2021123186A1 (en) 2019-12-20 2020-12-18 Multi-specific antibody with binding specificity for human il-13 and il-17

Publications (1)

Publication Number Publication Date
PE20221173A1 true PE20221173A1 (es) 2022-07-25

Family

ID=69323008

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001104A PE20221173A1 (es) 2019-12-20 2020-12-18 Anticuerpo multiespecifico con especificidad de union para il-13 e il-17 humanas

Country Status (19)

Country Link
US (2) US12570738B2 (cg-RX-API-DMAC7.html)
EP (1) EP4077381A1 (cg-RX-API-DMAC7.html)
JP (1) JP7689125B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220117307A (cg-RX-API-DMAC7.html)
CN (3) CN122541578A (cg-RX-API-DMAC7.html)
AR (1) AR120818A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020407279A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011627A2 (cg-RX-API-DMAC7.html)
CA (1) CA3164276A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022001685A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022009711A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22054471A (cg-RX-API-DMAC7.html)
GB (1) GB201919061D0 (cg-RX-API-DMAC7.html)
IL (1) IL294035A (cg-RX-API-DMAC7.html)
MX (1) MX2022007150A (cg-RX-API-DMAC7.html)
PE (1) PE20221173A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551411A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021123186A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202207715B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
US20240067758A1 (en) * 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
TW202613165A (zh) 2024-05-17 2026-04-01 比利時商Ucb生物製藥公司 具有il-11和il-17結合特異性的多特異性抗體

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
DE19653722C2 (de) 1996-12-10 2000-06-29 Brose Fahrzeugteile Beidseitig wirkende Verstellvorrichtung
CA2281794A1 (en) 1997-02-21 1998-08-27 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
EP1049787B1 (en) 1998-01-23 2004-11-24 Vlaams Interuniversitair Instituut voor Biotechnologie Multipurpose antibody derivatives
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US20040071705A1 (en) 2002-06-21 2004-04-15 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
GB0904214D0 (en) * 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
WO2011006915A2 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
PH12013501435B1 (en) * 2011-01-14 2019-02-01 UCB Biopharma SRL Antibody molecules which bind il-17a and il-17f
JP6411214B2 (ja) * 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック, インコーポレイテッド 抗il−13/il−17二重特異性抗体及びその使用
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
CN108064308B (zh) 2014-11-05 2023-06-09 豪夫迈·罗氏有限公司 细菌中产生双链蛋白的方法
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
WO2019220109A1 (en) * 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
WO2020010250A2 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody

Also Published As

Publication number Publication date
TW202130365A (zh) 2021-08-16
EP4077381A1 (en) 2022-10-26
IL294035A (en) 2022-08-01
BR112022011627A2 (pt) 2022-09-13
CN114846026B (zh) 2026-05-15
JP7689125B2 (ja) 2025-06-05
PH12022551411A1 (en) 2023-11-20
GB201919061D0 (en) 2020-02-05
CA3164276A1 (en) 2021-06-24
US20230087378A1 (en) 2023-03-23
AU2020407279A1 (en) 2022-08-11
MX2022007150A (es) 2022-07-19
KR20220117307A (ko) 2022-08-23
US20260226151A1 (en) 2026-08-06
CO2022009711A2 (es) 2022-07-19
ZA202207715B (en) 2024-01-31
CL2022001685A1 (es) 2023-05-26
ECSP22054471A (es) 2022-08-31
US12570738B2 (en) 2026-03-10
CL2023002975A1 (es) 2024-04-01
WO2021123186A1 (en) 2021-06-24
CN122502498A (zh) 2026-08-04
CN114846026A (zh) 2022-08-02
CN122541578A (zh) 2026-08-11
JP2023507280A (ja) 2023-02-22
AR120818A1 (es) 2022-03-23

Similar Documents

Publication Publication Date Title
PE20212324A1 (es) Anticuerpos que reconocen tau
CL2020003046A1 (es) Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018)
PE20251278A1 (es) Anticuerpos anti-tl1a y metodos de uso de los mismos
PE20080214A1 (es) Moleculas de anticuerpo que se unen a la il-17 humana
HRP20190932T1 (hr) Molekule protutijela koje se vežu na il-17a i il-17f
PE20200862A1 (es) Anticuerpos anti-trem2 y metodos relacionados
PE20181952A1 (es) Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
PE20121645A1 (es) Composiciones y metodos para tratar trastornos inflamatorios
AR080501A1 (es) Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1)
PE20210554A1 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
PE20070998A1 (es) Moleculas de anticuerpo que tienen especificidad para la il-6-humana
PE20190212A1 (es) Anticuerpos anti_ige
PE20121646A1 (es) Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
PE20191075A1 (es) Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo
PE20181089A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
PE20211767A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g
PE20220487A1 (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos
PE20231680A1 (es) Anticuerpos anti-cd30l y usos de estos
PE20211605A1 (es) ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS
PE20120211A1 (es) Anticuerpos que tienen especificidad por ox40 humana
MX2009012493A (es) Metodos de humanizacion de anticuerpo de conejo novedosos y anticuerpos de conejo humanizados.
AR115192A1 (es) Anticuerpos
AR105938A1 (es) Anticuerpo anti-epha4
PE20221151A1 (es) Anticuerpos anti-cd96 y sus metodos de uso